ASTRO: SABR Offers Long-Term Benefits Comparable to Surgery for Non-Small Cell Lung Cancer
For patients with non-small cell lung cancer, stereotactic ablative radiotherapy (SABR) offers long-term survival outcomes comparable to surgery.
A study presented at the annual meeting of the American Society for Radiation Oncology found that SABR provides long-term benefits similar to surgery for non-small cell lung cancer (NSCLC) patients.
- 80 patients were treated with SABR.
- A matched cohort of 80 patients underwent video-assisted thoracoscopic lobectomy with mediastinal lymph node dissection.
- Participants were followed for a median of 8.3 years.
Researchers found that 11 percent of patients undergoing surgery had occult lymph node involvement discovered on surgical pathology, and 14 percent received adjuvant therapy.
No direct quote available in the text.
Author's summary: SABR offers comparable long-term benefits to surgery for NSCLC patients.